Comparing the tested affibody variants with the HER3-targeting affibody MM-121, we could conclude that treatment with the monovalent 3A variant was equally potent as the treatment with MM-121, both regarding absolute tumor volume and median survival. This evidence concerns the gene ERBB3 and neoplasm.